Speculation soars over Pfizer's interest in biotech

The buzz over Pfizer's biopharma ambitions continues with analyst George Grofik speculating about the possibilities of a Biogen Idec acquisition versus, say, Amgen or Wyeth. Biogen Idec's starting price is around $23 billion, while Amgen could fetch $62 billion, give or take a few billion. Grofik is looking for a few bite-sized acquisitions followed by a mid-sized buyout for Pfizer. But that doesn't leave the pharma giant looking any better to the analyst. Grofik still has the company stock on "hold."

- read the report from the Wall Street Journal (sub. req.)

ALSO: It's official: Pfizer is killing off Exubera. Report

Related Articles:
Who should Pfizer buy? Report
Pfizer hires new R&D chief, launches biotech center. Report
Pfizer's future rests with biotech. Report
Biogen Idec in play after Icahn makes his move. Report

Read more on: Pfizer | Biogen Idec | Amgen | Wyeth

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.